Abstract
Purpose
Post-neurosurgical intracranial infection caused by carbapenem-resistant gram-negative bacteria (CRGNB) is a life-threatening complication. This study aimed to assess the current practices and clinical outcomes of intravenous (IV) combined with intraventricular (IVT)/intrathecal (ITH) polymyxin B in treating CRGNB intracranial infection.
Methods
A retrospective study was conducted on patients with post-neurosurgical intracranial infection due to CRGNB from January 2013 to December 2020. Clinical characteristics and treatment outcomes were collected and described. Kaplan–Meier survival and multivariate logistic regression analyses were performed.
Results
The study included 114 patients, of which 72 received systemic antimicrobial therapy combined with IVT/ITH polymyxin B, and 42 received IV administration alone. Most infections were caused by carbapenem-resistant Acinetobacter baumannii (CRAB, 63.2%), followed by carbapenem-resistant Klebsiella pneumoniae (CRKP, 31.6%). Compared with the IV group, the IVT/ITH group had a higher cerebrospinal fluid (CSF) sterilization rate in 7 days (p < 0.001) and lower 30-day mortality (p = 0.032). In the IVT/ITH group, patients with CRKP infection had a higher initial fever (p = 0.014), higher incidence of bloodstream infection (p = 0.040), lower CSF sterilization in 7 days (p < 0.001), and higher 30-day mortality (p = 0.005) than those with CRAB infection. Multivariate logistic regression analysis revealed that the duration of IVT/ITH polymyxin B (p = 0.021) was independently associated with 30-day mortality.
Conclusions
Intravenous combined with IVT/ITH polymyxin B increased CSF microbiological eradication and improved clinical outcomes. CRKP intracranial infections may lead to more difficult treatment and thus warrant attention and further optimized treatment.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Post-neurosurgical central nervous system (CNS) infection, a serious complication of neurosurgical procedures, is associated with high mortality, morbidity, and poor functional outcomes [1, 2]. In recent years, gram-negative pathogen-related ventriculitis/meningitis have been reported more frequently and have had worse clinical characteristics and prognostic outcomes than gram-positives [3,4,5]. To make things worse, the incidence of carbapenem-resistant gram-negative bacteria (CRGNB) is increasing worldwide [6, 7]. Clinically related CRGNB mainly include Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae, which are resistant to piperacillin, third-generation cephalosporins, carbapenems, and fluoroquinolones [8]. For the treatment of CRGNB infection, clinicians often resort to combination therapy based on polymyxins (colistin or polymyxin B), aminoglycosides, and tigecycline [9, 10]. However, these antibiotics were found to have inadequate penetration from the blood–brain barrier, making it difficult to achieve adequate cerebrospinal fluid (CSF) concentrations using systemic therapy [11]. Therefore, the choice of antibiotics for CRGNB ventriculitis/meningitis is extremely limited, greatly increasing the difficulty of treatment.
The presence of CRGNB has forced the use of topical therapies to achieve an effective therapeutic concentration of antibiotics at the site of infection [12]. Intraventricular (IVT) and intrathecal (ITH) therapies are widely recognized treatments for ventriculitis and meningitis, especially when the pathogen is carbapenem-resistant bacteria [13]. Such therapies bypass the blood–brain and blood–CSF barriers and overcome the limited penetration of antibiotics into the CSF, raise the respective drug concentrations, and minimize systemic toxicities [11, 14]. The current guideline recommends that the adjunct IVT/ITH antimicrobial therapy should be reserved for patients with infections caused by multidrug-resistant (MDR) gram-negative bacteria or for those who poorly respond to the standard intravenous agents [15]. Several studies have chosen IVT/ITH administration to achieve an adequate level of drugs in the CSF to combat these resistant organisms [16,17,18,19].
Because of its potent activity against CRGNB, polymyxin B is used as the last therapy after all other treatment schemes fail [20]. However, most previous studies have focused on the treatment of MDR A. baumannii infections with small samples, whereas the treatment of intracranial infections caused by other MDR gram-negative bacteria is extremely limited. In addition, there is a dearth of concrete evidence to determine the optimal dose and duration of IVT/ITH polymyxin B for patients with intracranial infection caused by CRGNB. To further confirm the efficacy and safety of the IVT/ITH strategy, we retrospectively analyzed the clinical features and eventual outcomes of 114 patients with post-neurosurgical intracranial infection caused by CRGNB.
Methods
Patients and definition
This retrospective study was conducted from January 2013 to December 2020 at the Second Affiliated Hospital of Zhejiang University, School of Medicine, which is a tertiary care hospital. All adult patients with a positive CSF culture for CRGNB after neurosurgery were enrolled. Patients with any of the following conditions were excluded: (i) less than 18 years of age; (ii) a polymicrobial result from CSF culture; (iii) possible contamination; (iv) IVT/ITH polymyxin B only once after the diagnosis of intracranial infection; or (v) incomplete clinical data. Each patient was included in the study only once at the time of the first positive CSF culture. The diagnosis and treatment management of intracranial infections and evaluation of the final outcomes were determined by physicians. After inclusion, patients were classified into two groups: patients receiving intravenous (IV) plus IVT/ITH polymyxin B (IVT/ITH group) and those who received only IV treatment (IV group). In the IVT/ITH group, the process of local injection of polymyxin B was that the clinician removed 5 mL of CSF via the ventricular drainage tube or lumbar cistern drainage tube and discarded it, then injected 5 mg/day of polymyxin B and finally closed the tube for 2 h. The clinician determined whether or not to change the dosing interval based on CSF results. Approval for this study was granted with waiver of individual consent by the Ethics Committee of the 2nd Affiliated Hospital, School of Medicine, Zhejiang University (No. 2023 − 0193).
CRGNB intracranial infection was defined in such a way that a positive culture of CRGNB from CSF cultures was found at least once, with increased white cells, decreased glucose, and/or increased protein levels in the CSF, as well as clinical symptoms suspicious for meningitis or ventriculitis [15]. If the patient did not exhibit clinical symptoms or had normal levels of glucose, protein, and nucleated cells, the positive CSF culture was regarded as contaminated. The clinical outcomes were defined as follows: (i) the 30-day mortality: death within 30 days after the first CSF bacterial culture was positive; (ii) CSF sterilization: a positive CSF culture, followed by at least one and all subsequent CSF cultures being negative after treatment [21].
Data collection
Data of the patients were extracted from electronic medical records, including demographics, primary disease, comorbidities, craniocerebral surgery, length of hospital stay, intensive care unit (ICU) admission, acute physiology and chronic health evaluation II (APACHE II) score, Glasgow coma scale (GCS) on admission, sequential organ failure assessment (SOFA) score using the worst physiological parameters within 24 h before the CSF culture was positive. The data were also extracted from laboratory test data, including CSF white blood cell count, CSF glucose, CSF protein levels, CSF bacterial culture results, antimicrobial use, and treatment efficacy.
Microbiology
Drug susceptibility tests were carried out using a VITEK 2 Compact automated microbiological analysis system (bioMérieux, France) or the disk diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) criteria in our microbiology laboratory. The results were interpreted in accordance with the CLSI 2021 criteria, and Enterobacteriaceae with minimum inhibitory concentration (MIC) ≥ 4 mg/L and A. baumannii and P. aeruginosa with MIC ≥ 8 mg/L were considered resistant to carbapenem [22].
Statistical analysis
Statistical analysis was performed using SPSS version 25.0. Measurement data were expressed as median and interquartile range (IQR) for continuous variables and percentages (%) for categorical variables. Normally distributed continuous variables were analyzed by the t test, while non-normally variables were analyzed by the Mann–Whitney test. The chi-square test and Fisher’s exact test were used to compare categorical variables. The 30-day survival was compared with Kaplan–Meier analysis and log-rank test. Variables with p-values < 0.1 were included in multivariate logistic regression to estimate odds ratios (ORs) for 30-day mortality. All p-values were two-tailed, and a p-value < 0.05 was considered statistically significant.
Results
Clinical characteristics
A total of 629 patients with positive CSF cultures were retrospectively reviewed, of which 515 were excluded, and 114 were finally enrolled. There were 72 patients in the IVT/ITH group, and 42 in the IV group (Fig. 1). The most prevalent reason for admission was cerebrovascular disease (65/114, 57.0%), followed by craniocerebral trauma (34/114, 29.8%) and intracranial tumors (15/114, 13.2%). A comparison of the clinical features of the two patient groups is revealed in Table 1. Compared with the IV group, patients in the IVT/ITH group were older (p < 0.001), and fewer patients received intravenous carbapenems (p = 0.038). There was a higher CSF sterilization in 7 days (p < 0.001), and lower 30-day mortality was observed (p = 0.032). In the IVT/ITH group, the median duration of IVT/ITH polymyxin B was 10 days, with a cumulative dose of 45 mg. Among them, one patient experienced tremors after ITH polymyxin B; the symptoms were mild and completely resolved after withdrawal.
Microbiology
All CSF cultured demonstrated CRGNB, including 72 cases (63.2%) of carbapenem-resistant A. baumannii (CRAB) infection, 36 (31.6%) of carbapenem-resistant K. pneumoniae (CRKP) infection, 4 (3.5%) of carbapenem-resistant P. aeruginosa (CRPA) infection, and 2 (1.8%) of other carbapenem-resistant Enterobacteriaceae (CRE) infection (Table 1). All A. baumannii and K. pneumoniae isolates were resistant to carbapenems and were susceptible to polymyxin B (Table 2).
CRKP and CRAB infections
In the IVT/ITH group, patients with CRKP infection tended to have a higher initial fever (p = 0.014), higher incidence of bloodstream infection (p = 0.040), and lower CSF sterilization in 7 days (p < 0.001) than those with CRAB infection. In addition, a significant difference was observed in males (p = 0.036), combined intravenous carbapenems (p = 0.015), and IVT/ITH administration (p = 0.035) between the two groups. Patients with CRKP infection had a higher 30-day mortality rate than those with CRAB infection (50.0% vs. 17.8%, p = 0.005; Table 3). Kaplan–Meier curves also demonstrated a significant difference between the two groups (p = 0.002; Fig. 2). However, no significant difference was found between CRAB and CRKP infections in the IV group (Table 3).
Factors related to 30-day all-cause mortality in patients with IVT/ITH polymyxin B
The 30-day all-cause mortality rate in patients treated with IVT/ITH polymyxin B was 27.8% (20/72). Univariate analysis depicted that CRKP infection (p = 0.003), bloodstream infection (p = 0.031), IVT or ITH administration (p = 0.027), duration of IVT/ITH polymyxin B (p = 0.008), combined intravenous carbapenems (p = 0.028), and CSF sterilization in 7 days (p = 0.009) were associated with 30-day mortality. Multivariate logistic regression analysis revealed that the duration of IVT/ITH polymyxin B (p = 0.021) was an independent risk factor associated with 30-day mortality (Table 4).
Discussion
This study retrospectively evaluated patients with post-neurosurgical intracranial infection caused by CRGNB and observed that patients receiving IVT/ITH polymyxin B had increased CSF microbiological eradication and reduced mortality. In addition, for patients receiving IVT/ITH administration, the mortality of patients with CRKP infection was significantly higher than that of patients with CRAB infection.
CRGNB is associated with increased mortality [23]. CRAB has become the most common pathogen for nosocomial intracranial infection neurosurgery wards [5, 24]. A retrospective study showed that the 30-day mortality of postoperative CNS infection caused by MDR/XDR A. baumannii was 28.6%, even after IVT/ITH administration [25]. Notably, the pathogenicity and toxicity of CRKP are higher than those of CRAB, resulting in high mortality [26]. A retrospective study displayed that ICU admission, bacteremia, and hospital-acquired pneumonia were risk factors for CRE meningitis, and the overall mortality of CRE meningitis/encephalitis was as high as 69.2% [27]. To date, few studies or cases have reported IVT/ITH administration in treating intracranial infections caused by CRKP, most of which were retrospective studies [28,29,30,31]. In our study, the mortality of patients with intracranial infections caused by CRKP remained high even with IVT/ITH polymyxin B, but we also found that patients with CRKP infection had more combined bloodstream infections than those with CRAB infection. Mortality in patients with CRGNB infection was linked to various factors, including age, SOFA score, Charlson Index and bacteremia [23, 32]. Consequently, large-scale clinical studies of CRKP intracranial infection are still needed.
Although the preferred approach for the treatment of CRGNB intracranial infections remains unclear, a combination of intravenous and IVT/ITH therapy may be necessary for optimal clinical outcomes [33]. Combining IVT with intravenous administration is likely to achieve higher antibiotic levels in CSF and more effective sterilization than IVT therapy alone [21, 34], This combination may help prevent compartments with subinhibitory antibiotic concentrations, thereby reducing the probability of the selection of resistant bacteria and relapse [35]. In a setting of high prevalence of nosocomial infections caused by CRGNB, polymyxins should be considered in combination with other drugs. Several in vitro and clinical studies have suggested the clinical benefits of adopting polymyxin–drug combination therapy, especially polymyxin plus meropenem, with synergistic killing against MDR/XDR gram-negative bacteria [36,37,38,39]. Although meropenem is recommended as the main empirical treatment for healthcare-associated ventriculitis and meningitis against gram-negative bacteria [40], resistance may lead to delayed treatment effectiveness and adverse outcomes. This study found no beneficial results for the combination of polymyxin B and carbapenems, even when carbapenem therapy was optimized, such as increasing the dose and extending the infusion. This indicates that optimizing the combination treatment regimen for intracranial infection caused by CRGNB is extremely challenging.
The current guideline suggests CSF antimicrobial concentrations of 10–20 times the MIC of the isolate and a daily IVT dose of 5 mg polymyxin B for gram-negative ventriculitis and meningitis [15]. The CSF antimicrobial concentrations are affected by the ventricular size and daily drain output, and drain clamping should be performed after each administration (15–60 min). IVT administration ensures distribution throughout CSF compartment, whereas ITH dosing often fails to attain adequate antibiotic concentrations in the ventricles [11]. However, this study did not find significant differences in clinical outcomes between these two regimens.
Prompt diagnosis and intervention using appropriate antibiotics are considered imperative. A case series and systematic review demonstrated that death was related to delayed ITH/IVT therapy compared with survival (7 vs. 2 days, p = 0.01) [41]. Furthermore, studies on the association between the timing of ITH/IVT administration and clinical outcomes are sparse. The results of this study showed that timely IVT/ITH treatment within 48 h of a positive CSF culture had no significant effect on clinical outcome.
The length of IVT delivery varied among the available studies, while the total treatment duration has often not been specified [13]. The current guideline recommends that adequate antimicrobial therapy should continue for 21 days by gram-negative bacilli and up to 10–14 days after the last positive culture in patients with repeatedly positive CSF cultures [15]. The median/mean duration of treatment with IVT/ITH polymyxins was 13–15 days in the current small retrospective study [18, 42, 43], which is similar to the results of this study.
In a recent meta-analysis, the incidence of complications in 229 patients with meningitis caused by gram-negative pathogens who received intrathecal administration was as high as 13%, and chemical meningitis and seizures represented the majority of the complications [44]. However, the adverse effects of IVT/ITH administration reported in previous studies were mainly due to colistin rather than polymyxin B [20]. Since patients receiving IVT/ITH therapy are usually in a coma or are sedated, adverse drug effects may have gone unnoticed or been attributed to complications of the underlying disease, and the true incidence of adverse effects of IVT/ITH therapy may be underestimated.
There are some limitations to the current study. First, this was a retrospective study with a small sample size in a single center and relied on clinical culture results, which may introduce bias in data interpretation. Second, as patients were seriously ill and other confounding factors were common in the ICU, we could not identify the impact of these factors on mortality. Third, the modified Rankin scale or Glasgow Outcome Scale were not used, as some patients may survive and present in a vegetative state, which is also a devastating outcome. Finally, the effect of ventricular size and daily CSF drainage volume on the outcome of IVT/ITH administration was not analyzed, and further multicenter randomized controlled studies are required.
Conclusions
Intravenous combined with IVT/ITH polymyxin B increased CSF microbiological eradication and reduced mortality. CRKP intracranial infection may lead to more difficult treatment and worse outcome, requiring attention and further optimized treatment.
Data availability
The datasets generated during and/or analyzed during the current study are not publicly available due to institutional ethics, privacy, and confidentiality regulations, but are available from the corresponding author on reasonable request.
References
Hasbun R (2021) Healthcare-associated ventriculitis: current and emerging diagnostic and treatment strategies. Expert Rev Anti Infect Ther 19(8):993–999. https://doi.org/10.1080/14787210.2021.1866544
Karvouniaris M, Brotis A, Tsiakos K, Palli E, Koulenti D (2022) Current perspectives on the diagnosis and management of healthcare-associated ventriculitis and meningitis. Infect Drug Resist 15697–15721. https://doi.org/10.2147/idr.s326456
Kurtaran B, Kuscu F, Ulu A et al (2018) The causes of postoperative meningitis: the comparison of Gram-negative and gram-positive pathogens. Turk Neurosurg 28(4):589–596. https://doi.org/10.5137/1019-5149.jtn.20575-17.1
Panic H, Gjurasin B, Santini M, Kutlesa M, Papic N (2022) Etiology and outcomes of healthcare-associated meningitis and ventriculitis-a single center cohort study. Infect Dis Rep 14(3):420–427. https://doi.org/10.3390/idr14030045
Sipahi OR, Nazli Zeka A, Taşbakan M et al (2017) Pooled analysis of 899 nosocomial meningitis episodes from Turkey. Turk J Med Sci 47(1):29–33. https://doi.org/10.3906/sag-1508-102
Paul M, Daikos GL, Durante-Mangoni E et al (2018) Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 18(4):391–400. https://doi.org/10.1016/s1473-3099(18)30099-9
Tompkins K, van Duin D (2021) Treatment for carbapenem-resistant enterobacterales infections: recent advances and future directions. Eur J Clin Microbiol Infect Dis 40(10):2053–2068. https://doi.org/10.1007/s10096-021-04296-1
Fritzenwanker M, Imirzalioglu C, Herold S, Wagenlehner FM, Zimmer KP, Chakraborty T (2018) Treatment options for carbapenem- resistant gram-negative infections. Dtsch Arztebl Int 115(20–21):345–352. https://doi.org/10.3238/arztebl.2018.0345
Papst L, Beović B, Pulcini C et al (2018) Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect 24(10):1070–1076. https://doi.org/10.1016/j.cmi.2018.01.015
Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL (2019) Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect 25(8):951–957. https://doi.org/10.1016/j.cmi.2019.03.014
Nau R, Blei C, Eiffert H (2020) Intrathecal antibacterial and antifungal therapies. Clin Microbiol Rev 33(3). https://doi.org/10.1128/cmr.00190-19
Kim BN, Peleg AY, Lodise TP et al (2009) Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis 9(4):245–255. https://doi.org/10.1016/s1473-3099(09)70055-6
Karvouniaris M, Brotis AG, Tsiamalou P, Fountas KN (2018) The role of intraventricular antibiotics in the treatment of nosocomial ventriculitis/meningitis from gram-negative pathogens: a systematic review and meta-analysis. World Neurosurg 120e:637-e650. https://doi.org/10.1016/j.wneu.2018.08.138
Heffernan AJ, Roberts JA (2021) Dose optimisation of antibiotics used for meningitis. Curr Opin Infect Dis 34(6):581–590. https://doi.org/10.1097/qco.0000000000000783
Tunkel AR, Hasbun R, Bhimraj A et al (2017) 2017 infectious diseases society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis 64(6):e34–e65. https://doi.org/10.1093/cid/ciw861
Karaiskos I, Galani L, Baziaka F, Giamarellou H (2013) Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents 41(6):499–508. https://doi.org/10.1016/j.ijantimicag.2013.02.006
De Bonis P, Lofrese G, Scoppettuolo G et al (2016) Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter baumannii meningitis. Eur J Neurol 23(1):68–75. https://doi.org/10.1111/ene.12789
Khan SA, Waqas M, Siddiqui UT et al (2017) Intrathecal and intraventricular antibiotics for postoperative Gram-negative meningitis and ventriculitis. Surg Neurol Int 8226. https://doi.org/10.4103/sni.sni_81_17
Pan S, Huang X, Wang Y et al (2018) Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii: a retrospective cohort study. Antimicrob Resist Infect Control 78. https://doi.org/10.1186/s13756-018-0305-5
Velkov T, Dai C, Ciccotosto GD, Cappai R, Hoyer D, Li J (2018) Polymyxins for CNS infections: Pharmacology and neurotoxicity. Pharmacol Ther 18185–18190. https://doi.org/10.1016/j.pharmthera.2017.07.012
Lewin JJ III, Cook AM, Gonzales C et al (2019) Current practices of Intraventricular antibiotic therapy in the treatment of meningitis and ventriculitis: results from a multicenter retrospective cohort study. Neurocrit Care 30(3):609–616. https://doi.org/10.1007/s12028-018-0647-0
CLSI (2021) Performance standards for antimicrobial susceptibility testing. M100, 31st edn. Clinical and Laboratory Standards Institute, Wayne, PA
Falcone M, Tiseo G, Carbonara S et al (2023) Mortality attributable to Bloodstream infections caused by different carbapenem-resistant gram-negative Bacilli: results from a nationwide study in Italy (ALARICO Network). Clin Infect Dis 76(12):2059–2069. https://doi.org/10.1093/cid/ciad100
Ye Y, Kong Y, Ma J, Shi G (2022) Carbapenem-resistant gram-negative bacteria-related healthcare-associated ventriculitis and meningitis: antimicrobial resistance of the pathogens, treatment, and outcome. Microbiol Spectr 10(3):e0025322. https://doi.org/10.1128/spectrum.00253-22
Liang W, Yuan-Run Z, Min Y (2019) Clinical presentations and outcomes of post-operative central nervous system infection caused by Multi-Drug-Resistant/Extensively drug-resistant Acinetobacter baumannii: a retrospective study. Surg Infect (Larchmt) 20(6):460–464. https://doi.org/10.1089/sur.2018.286
Brink AJ (2019) Epidemiology of carbapenem-resistant Gram-negative infections globally. Curr Opin Infect Dis 32(6):609–616. https://doi.org/10.1097/qco.0000000000000608
Guanghui Z, Jing L, Guojun Z, Hong L (2020) Epidemiology and risk factors of neurosurgical bacterial meningitis/encephalitis induced by carbapenem resistant Enterobacteriaceae. J Infect Chemother 26(1):101–106. https://doi.org/10.1016/j.jiac.2019.07.023
Kizilates F, Keskin AS, Onder KD (2021) Clinical features of post-operative nosocomial meningitis in adults and evaluation of efficiency of Intrathecal Treatment. Surg Infect (Larchmt) 22(10):1059–1063. https://doi.org/10.1089/sur.2021.024
Liu D, Niu J, Chen G, Xu L (2022) Treatment of carbapenem-resistant multidrug-resistant gram-negative bacilli with intracerebroventricular injection of polymyxin B: a retrospective study. Infect Drug Resist 157653–157666. https://doi.org/10.2147/idr.s392818
Yue Z, Zhi X, Bi L, Zhao L, Ji J (2023) Treatment and prognostic risk factors for intracranial infection after craniocerebral surgery. Neurosurg Rev 46(1):199. https://doi.org/10.1007/s10143-023-02106-0
Iaria C, Giammalva GR, Spicola D et al (2021) Multidrug-resistant Gram-negative post-neurosurgical meningitis and the role of intraventricular colistin: a case series. Infez Med 29(1):130–137
Wang M, Ge L, Chen L et al (2023) Clinical outcomes and bacterial characteristics of carbapenem-resistant acinetobacter baumannii among patients from different global regions. https://doi.org/10.1093/cid/ciad556
Tsuji BT, Pogue JM, Zavascki AP et al (2019) International Consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for anti-infective pharmacology (ISAP), society of critical Care Medicine (SCCM), and Society of Infectious diseases pharmacists (SIDP). Pharmacotherapy 39(1):10–39. https://doi.org/10.1002/phar.2209
Ziaka M, Markantonis SL, Fousteri M et al (2013) Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. Antimicrob Agents Chemother 57(4):1938–1940. https://doi.org/10.1128/aac.01461-12
Nau R, Seele J, Djukic M, Eiffert H (2018) Pharmacokinetics and pharmacodynamics of antibiotics in central nervous system infections. Curr Opin Infect Dis 31(1):57–68. https://doi.org/10.1097/qco.0000000000000418
Olsson A, Hong M, Al-Farsi H, Giske CG, Lagerbäck P, Tängdén T (2021) Interactions of polymyxin B in combination with aztreonam, minocycline, meropenem, and rifampin against escherichia coli producing NDM and OXA-48-group carbapenemases. Antimicrob Agents Chemother 65(12):e0106521. https://doi.org/10.1128/aac.01065-21
Diep JK, Jacobs DM, Sharma R et al (2017) Polymyxin B in combination with rifampin and meropenem against polymyxin B-resistant KPC-producing klebsiella pneumoniae. Antimicrob Agents Chemother 61(2). https://doi.org/10.1128/aac.02121-16
Ardebili A, Izanloo A, Rastegar M (2023) Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy? Expert Rev Anti Infect Ther 21(4):387–429. https://doi.org/10.1080/14787210.2023.2184346
Abdelsalam MFA, Abdalla MS, El-Abhar HSE (2018) Prospective, comparative clinical study between high-dose colistin monotherapy and colistin-meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist 15127–15135. https://doi.org/10.1016/j.jgar.2018.07.003
Ciummo F, Srinivas P, Biedny J (2021) Antimicrobial use in central nervous system infections. Curr Opin Infect Dis 34(3):255–263. https://doi.org/10.1097/qco.0000000000000721
Khawcharoenporn T, Apisarnthanarak A, Mundy LM (2010) Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review. Clin Microbiol Infect 16(7):888–894. https://doi.org/10.1111/j.1469-0691.2009.03019.x
Tsimogianni A, Alexandropoulos P, Chantziara V et al (2017) Intrathecal or intraventricular administration of colistin, Vancomycin and amikacin for central nervous system infections in neurosurgical patients in an intensive care unit. Int J Antimicrob Agents 49(3):389–390. https://doi.org/10.1016/j.ijantimicag.2017.01.002
Li H, Yu W, Wang G, Cai H (2022) Outcome of using intraventricular plus intravenous polymyxin B in post-neurosurgical patients with multi/extensively drug-resistant gram-negative bacteria-induced intracranial infection. Front Med (Lausanne) 9913364. https://doi.org/10.3389/fmed.2022.913364
Brotis AG, Churis I, Karvouniaris M (2021) Local complications of adjunct intrathecal antibiotics for nosocomial meningitis associated with gram-negative pathogens: a meta-analysis. Neurosurg Rev 44(1):139–152. https://doi.org/10.1007/s10143-019-01226-w
Acknowledgements
We would like to thank Prof. Hongwei Zhou, the Department of Laboratory Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, for the interpretation of the microbiological results.
Funding
This study was supported by the Zhejiang Provincial Natural Science Foundation of China under Grant No. LYY22H310016.
Author information
Authors and Affiliations
Contributions
Yangmin Hu contributed to design and drafting of the article; Danyang Li and Gensheng Zhang contributed to the revision of the intellectual content; Yunjian Dai, Meng Chen and Huifang Jiang contributed to data collection and analysis, Wei Cui supervised the research and revised the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
The study was approved with waived of informed consent by the Ethics Committee of the 2nd Affiliated Hospital, School of Medicine, Zhejiang University (No. 2023 − 0193). As this was a noninterventional, retrospective study with data management processed anonymously, informed consent was waived.
Consent for publication
Not applicable.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Hu, Y., Li, D., Zhang, G. et al. Intraventricular or intrathecal polymyxin B for treatment of post-neurosurgical intracranial infection caused by carbapenem-resistant gram-negative bacteria: a 8-year retrospective study. Eur J Clin Microbiol Infect Dis 43, 875–884 (2024). https://doi.org/10.1007/s10096-024-04794-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-024-04794-y